BriaCell Therapeutics Corp.
BCTX
$4.35
-$0.06-1.36%
NASDAQ
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -72.99% | -449.14% | -224.13% | 8.05% | -25.77% |
| Total Depreciation and Amortization | 0.09% | 27.45% | 903.29% | 752.63% | 601.97% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 93.64% | 99.78% | 85.95% | 13.49% | -9.73% |
| Change in Net Operating Assets | -91.02% | -127.04% | -156.24% | 280.17% | 221.63% |
| Cash from Operations | -23.19% | -16.76% | 22.37% | 29.63% | 15.58% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2,448.67% | -3,298.22% | -13.33% | -- | -- |
| Cash from Investing | -910.31% | -1,021.44% | -216.36% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 104.45% | 928.50% | 807.76% | 439.68% | 309.32% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 104.45% | 928.50% | 807.76% | 439.68% | 309.32% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 60.80% | 147.24% | 142.32% | 95.48% | 67.01% |